Watson Pharmaceuticals – Initiation of Esmya(R) U.S. Phase 3 Clinical Trial – WPI
Watson Pharmaceuticals, Inc. (NYSE: WPI) announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya® (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition...